Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 8119130 Targeted binding agents directed to KDR and uses thereof—035

Patent 8119130 was granted and assigned to Medimmune Limited on February, 2012 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Patent abstract

The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 8119130 Targeted binding agents directed to KDR and uses thereof—035

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo